PHARMACY

Walgreens kicks off vaccination campaign

BY Lesley Thulin

DEERFIELD, Ill. — Walgreens kicked off its third Get a Shot. Give a Shot campaign on Wednesday. This year’s campaign promises to provide a life-saving vaccine for every immunization administered at any Walgreens pharmacy, Healthcare Clinic or Duane Reade until Aug. 31, 2016.

Donations will be made through the United Nations Foundation’s Shot@Life campaign.

“Get a Shot. Give a Shot demonstrates the important role our customers can play, and how a flu shot or other immunization can truly make a world of difference,” Walgreens president Alex Gourlay said. “We’re extremely proud of the global impact the program has made. And as we expand our relationship with the UN Foundation, our objective is to also increase our donation over last season to help provide more life-saving vaccines to children who need them most.”

Around the world, 1 in 5 children cannot access life-saving immunizations, and a child dies every 20 seconds from a vaccine-preventable disease, according to Walgreens. 

"Vaccines protect and improve the lives of millions of children in developing countries each year,” Kathy Calvin, president and CEO of the UN Foundation, said. “The prevention of measles deaths has been the single largest contributor to reducing childhood deaths over the last decade and we are now so close to ending polio. By expanding our partnership with Walgreens, we can support UN efforts to help children access these life-saving vaccines around the globe.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Novartis, Amgen team on migraine, Alzheimer’s drug development

BY David Salazar

BASEL, Switzerland — Novartis and Amgen are joining forces to develop and commercialize neuroscience treatments in both their pipelines the companies announced Tuesday. The collaboration will see them working on a BACE inhibitor program to treat Alzheimer’s disease and developing Amgen’s migraine drugs.

"This Novartis collaboration with Amgen highlights our clear commitment to neuroscience and to bring multiple, new targeted therapies to patients living with Alzheimer's disease and migraine, where the unmet medical need remains high." Novartis Pharmaceuticals head David Epstein said.

The Amgen partnership comes on the heels of Novartis’ recent acquisition of Spinifex Phamceuticals, which added a compound for neuropathic pain to the company’s portfolio, and its agreement to acquire multiple sclerosis treatment Ofatumumab from GlaxoSmithKline. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

QS1 offers myDataMart through FDS partnership

BY David Salazar

SPARTANBURG, S.C. — QS1 announced Wednesday that it would be partnering with business solutions company FDS to brings its customers FDS’s business intelligence software myDataMart. Using myDataMart, pharmacy owners can receive detailed analytics into the state of their business operations and potentially increase their Centers for Medicare and Medicaid Services Star ratings, QS1 said. 
 
“We are pleased to partner with FDS, a company that understands our commitment to offering the most advanced technology for our customers to efficiently run their businesses,” QS1 senior manger of marketing and analytics, Michael Ziegler, said.
 
myDataMart can be combined with QS1’s other dashboards and graphical support that the company said can aid in monitoring adherence among patients, Star rating measures and dispensing analysis. 
 
“QS/1 is always looking for ways to help our pharmacy customers succeed,” Ziegler added. “Improving adherence and Five-Star Quality Ratings will be an integral part of long-term success and growth. This partnership will build upon the resources already offered by QS/1.” 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?